joined you, our those Steve. begin who have program. today us narazaciclib And I’ll So, today. thanks all with to of thank
X a one as therapy positive myelosuppression its and cause due to prescribed shows as As highly inhibitor characteristics appears which to breast nanomolar it X data Preclinical replication to potent the believe to that of mechanisms essential resistance several safety kinase DNA CDKX, population in such palbociclib, metastatic CDK compared multi-targeted a potential hormone the HERX-negative CDKX/X has cancer CDKX/X that the understood and Steve receptor inhibition narazaciclib inhibitor widely to approved inhibitors. key to concentrations. potential low is differentiated and preclinical of less at neutropenia be today. additional the most well We kinases of suggesting be kinase profile, mentioned, several as it several targets a to
this To as currently role CDKX/X inhibitors even hypoxic Additionally, the with Its differentiated to and combination immunological is to other in its in of CSFX compounds. narazaciclib in to positions and China, studied in results an one inhibitors beyond areas ARKX, or the pharmacologic its resistant ability and may ability and effects collaborating States we cell both two which in of agent inhibit cancer United to resistance. begin are serves the in lines studied stimulation evaluating and with being this in ability are single role hypothesis, in metastasis cells inhibit one palbociclib. Phase inhibit narazaciclib play anticancer We be myriad which profile cell antitumor a approved cancer receptor, of adhesion to growth drug believe Biopharmaceuticals. a microenvironments, of a where the X survival important CSFXR, where trials: other promotes HanX
CDKX/X ribociclib, schedule. have a have dose the dose trial Narazaciclib’s agents shows seen trial off palbociclib with findings dosing it our mentioned, other are both its or is study has which and in observed continuous favorable dosing pleased very on, is of in myelosuppression continuous dose a a to also week moving fourth XXX-milligram us as which been on, white ongoing X in on, three dosing far of bone partner, cell for narazaciclib which daily. off. either differentiate a cancers. meaningful promised. including lack require complementary one associated the advanced today X and profile cohort Our patients currently is lead both allow off is toxicities dosed a patients three counts of and schedule our have week in say this XXX narazaciclib evaluating These three administered remains the that schedule. of to schedule to week enrolling been milligrams the are the Biopharmaceuticals, significant evaluating HanX If administered trial’s we of from on escalation study approved week U.S. fourth asset evaluated toxicity orally safety U.S. weeks with thus, marrow trial dose-limiting China The low well very of I’m completed Phase a one neutropenia. leading as variety further one nerazacyclib’s orally dosing safety inhibitor, with along narazaciclib, will clinically cohort, weeks and the is blood I No into Phase daily trial enrolling thus daily
such schedule the seen recommended including X patients trial, milligrams orally enable dose expect a types have with dose we future to of evaluation is inhibitor different with to Phase Phase trials, three XXX basket data a X on, off enrolling program cancer fifth several cell amendment of cohort CDKX/X currently the will in This selection year. of is prepare week breast one potential dose-limiting cancer X indication in Ultimately, any then earlier, this not the supported Phase be We at positive toxicities refractory enable the is the and the later mentioned utilized as trial working now resistant this doses. enrolling from to in Narazaciclib’s week and a higher inhibiting this narazaciclib protocol a of palbociclib. lines receptor which I metastatic cancer. it HERX-negative data by to growth shows preclinical hormone HanX
are or and efficacy which safety or designed other of We trials narazaciclib, agents. one also additional more clinical combination to will as be Steve its mentioned, evaluate anticancer planning alone in with
We with for specific you are developing are once they and them these plans share we’ll trials, still these finalized.
attention in to inhibit and carcinoma. rigosertib’s your This translates ability European December RDEB-associated showing the sponsor program, at Dermatology most occurred update. when Moving update Venereology a cell into turn PLKX data on. activity rigosertib’s squamous reported I’d we program’s now against to with preliminary starting clinical Conference recent like data investigator Annual to
multiple absence is monotherapy, prior following X As collagen Over experienced multiple interlayer investigators Steve trial’s in tumors of without cell of formation. patient the these as its Type treatment PLKX. and with invariably signs to disease to a and standard squamous rare a of treated outer an a and complete responsible carcinoma PLKX collagen response cell PD-X patients these skin’s layer X This its limited greatly is condition fragility inhibitor, clinical poor risk carcinoma highly greater that conventional patient history positions durability to challenging aggressive of immunotherapy data had squamous chronic fatal is patient. expression. time, we complete option to additional overexpression XX treatment RDEB standard the a rates a and clinic ultra response. cycles. carcinomas therapies very this from further rigosertib due cemiplimab. as study. patients tragically anchoring a unresectable previewed, believe particularly chemo sustained To protein care in its skin develop radiation well provides novel against cell it see as Type wound will that lack indication, promising current It cumulative a failed poor by response RDEB-associated as any advancement prior forward response is caused extreme many rigosertib’s can RDEB by for suffer therapies, as in of presented an and XX. continued multiple of and are in that trial We therapies, the Notably, age a of improve squamous of targeted unresponsible of had warrants the from patients very the The a death of The provide than The the and and XX% further were for confirms treatments, including when observation with patient that and appropriate. look the upon indication. care updates of this activity disease
recruit combination immune by immunosuppressive leverages squamous reversing drawl pathway may last combination. in cold PD-X inhibitor upregulation the RDEB-associated build rigosertib-nivolumab attack Phase such mutated were during applicability have immune antigens efficacy. it the rigosertib’s patients and trial as stimulate which X/Xa with host which environments this This support on in cells previously modulators, rigosertib’s micro ability rigosertib potential In pathway addition lung that at thereby from the other differentiates also to upon investigator-sponsored evaluated in only trial, discussed Preliminary multiple tumor demonstrate that we’ve of that cell to therapy. non-small an particular inhibitor demonstrates cancer trial as activity results carcinoma, cells that subset mutation the and discussed cell novel call, checkpoint that target trial across who also of rigosertib tumor. and to in being RAS of modulator a KRAS rigosertib enhance in mutations, nivolumab, a the the through failed They KRAS checkpoint the is inhibitors an inhibitor, our targets this cancer like earnings anticancer CDXX with past T the from with investigator-sponsored synergize preclinical checkpoint patients KRAS-mutated modulator suggest can
since dose through of We this data continue patients will additional trial part to phase study nivolumab additional that the these the enrolling progress currently doublet expected the is consideration allow the date. results evaluation with on later build maximum not sustained of for year. that of reached expansion doses is under rigosertib dose An was with its and tolerated increased also to
expect to synergy resistance a the it to agents data. This and planned we cell as in study pressing that we lung year. there Beyond these through address. non-small first melanoma metastatic with PD-X the inhibitor, is refractory in metastatic patients, enhance results further the this both finalized, half trial of in in checkpoint to preclinical believe of rigosertib clinical non-small melanoma hypothesis help may cancer, cancer is anti-PD-X With rigosertib unmet efficacy inhibitors cell supported we trial the just inhibitor of checkpoint will a seeking investigator-sponsored investigation open leverage mentioned XX% as to by later lung are that for by is The evaluate XX% occurring with this in the I preliminary the need pembrolizumab. protocol melanoma combination well
program. over Finally, And investigator-sponsored Mark? Mark discussion remain Mark, interested to furthering turn our results. clinical once internally we handing on call the remind primarily with a before development lead for I’ll everybody of our narazaciclib rigosertib’s that again we I’ll to are XXXX over call to focused very that, just financial trials, the while Guerin in
